[1. Balogova S, Kobetz A, Huchet V, Michaud L, Kerrou K, Paycha F, et al. Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l’enregistrement de la fluorocholine (18F): analyse sur deux ans à l’hôpital Tenon. Méd Nucl 2012; 36: 363-70.]Search in Google Scholar
[2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10: 1081-7.]Search in Google Scholar
[3. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med 2006; 47: 287-97.]Search in Google Scholar
[4. Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55: 448-57.]Search in Google Scholar
[5. Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging 2011; 55: 374-410.]Search in Google Scholar
[6. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med 2008; 49: 1928-35.]Search in Google Scholar
[7. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-80.]Search in Google Scholar
[8. McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, et al. ¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castrationresistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011; 38: 14-22.]Search in Google Scholar
[9. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623-8.]Search in Google Scholar
[10. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006; 8: 43-8.]Search in Google Scholar
[11. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33: 1387-98.]Search in Google Scholar
[12. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of (18F)-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 253-63.]Search in Google Scholar
[13. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008; 113: 895-904.]Search in Google Scholar
[14. Hodolič M. Role of (18)F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011; 45: 17-21.]Search in Google Scholar
[15. Huchet V, Gutman F, Kerrou K, Cussenot O, Haab F, Doublet J, et al. Evaluation of PSA velocity as a selection criterion for FCH PET/CT in patients with biological recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34(Suppl 2): S123.]Search in Google Scholar
[16. Hodolic M, Maffione A, Fettich J, Gubina B, Cimitan M, Rubello D. Metastatic prostate cancer proven by 18F-FCH PET/CT staging csan in patient with doubling time. Clin Nucl Med 2013; 38: 739-40.]Search in Google Scholar
[17. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-33.]Search in Google Scholar
[18. Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen, et al. [18F]fluoromethylcholine (FCH) positron emission tomography/ computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012; 110: 1666-71.]Search in Google Scholar
[19. Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/ computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110: 1501-6.]Search in Google Scholar
[20. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010; 57: 551-8.]Search in Google Scholar
[21. Lavery HJ, Brajtbord JS, Levinson AW, Nabizada-Pace F, Pollard ME, Samadi DB. Unnecessary imaging for the staging of low-risk prostate cancer is common. Urology 2011; 77: 274-8.]Search in Google Scholar
[22. Cook GJ, Venkitaraman R, Sohaib AS, Lewington VJ, Chua SC, Huddart RA. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging 2011; 38: 7-13.]Search in Google Scholar
[23. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castrationresistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17: 4854-61.]Search in Google Scholar
